Allergy Delabeling in Antibiotic Stewardship - Evaluations

Conditions

• Beta Lactam Allergy in Patients With a Hematologic Malignancy

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Semi-structured interview — BEHAVIORAL
  Interviews designed to obtain information about patient reasons for enrolling or declining participation in the RENEW Intervention
• Survey — BEHAVIORAL
  Survey which will incorporate a series of closed-ended questions eliciting attitudes about the feasibility and acceptability of the intervention, allergy delabeling and future BL antibiotic use
• Ethnographic observation — BEHAVIORAL
  Observations designed to identify communication and contextual barriers to the implementation of RENEW
• Survey — BEHAVIORAL
  Survey instruments will measure knowledge,attitudes, and practices surrounding allergy delabeling and antibiotic stewardship in patients with HM and perceptions of the feasibility and acceptability of the RENEW intervention
• Semi-structured interview — BEHAVIORAL
  Interviews designed to obtain information from clinicians about their perception of the implementation of the RENEW intervention

Study Details

The goal of this RENEW-EVAL project is to understand the potential barriers to implementation of the RENEW intervention into the routine clinical care of patients with a hematological malignancy.

Key Dates

Start date

Dec 1, 2025

Status verified

Jun 2026

Primary completion

Sep 30, 2028

Completion

Oct 31, 2029

Study Design

Enrollment

80 participants (estimated)

Arms

• Arm: Patients who enroll in the RENEW intervention
  Patients who agree to actively participate in the RENEW intervention designed to identify opportunities to have the beta lactam allergy label removed from their electronic medical record.
• Arm: Patients who decline enrollment in the RENEW intervention
  Patients who were approached for enrollment in the RENEW intervention but declined consent.
• Arm: Clinicians
  Clinicians who provide clinical care to patients enrolled in the intervention.
• Arm: RENEW Clinical Pharmacist
  The RENEW Clinical Pharmacist will screen, recruit, and consent potential participants and perform the RENEW intervention.

Primary Outcome Measure

Feasibility of Implementation [ Time Frame: From baseline Month 1 to Month 36 ]

Locations (1)

Find similar trials in Philadelphia, PA